Article
Direct oral anticoagulants may be safe in cancer-related venous thromboembolisms, but use caution with gastrointestinal malignancies
February 3, 2022
Clinical question: Are direct oral anticoagulants (DOACs) a suitable alternative to low molecular weight heparin (LMWH) for treatment of venous thromboembolism (VTE) in patients with underlying...
News
D-dimer thresholds rule out PE in meta-analysis
December 14, 2021
Data from a large review support use of D-dimer levels to diagnose PE without imaging.
![1]()
News
Anticoagulant choice in antiphospholipid syndrome–associated thrombosis
December 10, 2021
Are direct oral anticoagulants (DOACs) as efficacious and safe as vitamin K antagonists (VKAs) in treating thrombosis secondary to antiphospholipid syndrome (APS)?
![1]()
News
Apixaban a reasonable alternative to warfarin in patients with severe renal impairment
December 9, 2021
Is apixaban a safe alternative to warfarin in patients with severe renal impairment?
![1]()
News
Apixaban outmatches rivaroxaban for VTE in study
December 6, 2021
These real-world findings may guide selection of initial anticoagulant therapy, according to authors of the paper.
![1]()
News
Apixaban noninferior to low-molecular-weight heparin in cancer-associated VTE
December 6, 2021
Is oral apixaban as safe and effective as subcutaneous dalteparin in treating venous thromboembolism (VTE) in patients with underlying cancer?
![1]()
News
Ticagrelor reversal agent achieves quick hemostasis: REVERSE-IT
November 17, 2021
The monoclonal antibody bentracimab, which can rapidly reverse ticagrelor, was found effective and safe in an FDA-requested interim analysis of a phase 3 trial.
News
D-dimer unreliable for ruling out pulmonary embolism in COVID-19
October 14, 2021
“These results suggest that use of D-dimer levels to exclude PE among patients hospitalized with COVID-19 may be inappropriate and have limited clinical utility.”
![1]()
News
Autopsy findings reveal venous thromboembolism in patients with COVID-19
October 12, 2021
What pathologic features contribute to the cause of death in COVID-19?
News
Rivaroxaban’s single daily dose may lead to higher bleeding risk than other DOACs
October 11, 2021
Corroborating previous studies, Iceland researchers report that rivaroxaban poses the highest risk of GI bleeding, compared with other DOACs.
